首页 | 本学科首页   官方微博 | 高级检索  
     


High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types
Affiliation:1. Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, USA;2. Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA;3. Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, USA;4. Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, USA;5. Division of Tumor Biology & Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands;6. Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands;7. Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, The Netherlands;8. Oncode Institute, Utrecht, The Netherlands;9. Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands;10. The Preston Robert Tisch Brain Tumor Center, Duke University, Durham, USA;11. Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, USA;12. Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA;13. Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA;14. Department of Integrative Biology and Pharmacology, The University of Texas Health Sciences Center at Houston, Houston, USA;15. Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, USA
Abstract:
Keywords:immune checkpoint blockade  tumor mutation burden  biomarker
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号